COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > Cash

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Nov 12, 2024 12:43pm

47 Views

Post# 36308504

RE:RE:RE:RE:Cash

Stinzo wrote: The company has become less liquid then previously. There is 0 interest.

They've never released data on the avenanthramide pill. Is it worth anything when the Phase I/IIa safety/tolerability and preliminary efficacy data is released? Theoretically a proof of principle could be established.

The 100L PGX scale-up is also the decision point for mass industrialization. How compelling will the results be? They've got 50L headed towards small-scale commercialization. PGX will be commercial for the first time as they reach 100L capacity. What is the interest in licensing PGX? WWhat are the plans moving forward? DO they have the potential gold standard

The above milestones with a new President and CEO will make the story.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading